Lonza delivers strong 1st-half 2026 performance
Swiss contract development and manufacturing group Lonza (SWX: LONN) today reported sales of 3.4 billion francs ($4.25 billion) in the first half of 2026, reflecting a strong H1-weighted constant exchange rates (CER) sales growth of +16.0% (+11.2% AER) due to favorable phasing and a lower first half 2025 base.
A core earnings before interest, taxes, depreciation and amortization (EBITDA) of 1.2 billion francs (+27.4% versus first half 2025) resulted in a margin increase of +4.4ppts to 34.8%., the company noted. Despite the positive results, Lonza’s shares were down 4% at 541.20 francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze